BPC 157 + TB-500
Repair / recovery market
A common research market pairing. No approved combination product and no controlled combination evidence establishing the marketed use.
High exposure · evidence gapWHAT ARE PATIENTS ASKING ABOUT?
Exposure and combination surveillance
Market familiarity is not clinical evidence. FDA committee consideration of a nominated bulk substance is not FDA drug approval.
Observed combination signals
BPC 157 + TB-500 + GHK-Cu + KPV
Repair / inflammatory market
Observed as KLOW style market architecture. Four components compound questions of identity, attribution, stability and sterility.
High complexity · high governance needCJC-1295 no DAC + ipamorelin
Growth hormone axis
A frequently described clinic and research pairing. Component rationale is not validation of a fixed premixed formulation.
Established market patternTesamorelin + AOD-9604 + MOTS-c
Body composition / metabolic
Publicly described in clinic practice. Tesamorelin has an authorised US indication; that does not validate this three component stack.
Approved component · unapproved combinationEpitalon + Pinealon + Selank
Sleep / resilience
A clinic described architecture with limited component evidence and no controlled combination trial establishing the stack.
Practice signal · weak combination evidencePT-141 + oxytocin + Selank
Sexual health / bonding
Bremelanotide has an FDA approved indication, but a multi agent nasal combination is a different product and evidence question.
Strong component precedent · weak stack evidenceRegulatory surveillance cohorts
BPC 157
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordKPV
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordTB 500
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordMOTS-c
FDA PCAC reviewed 503A bulk substance nominations in July 2026
Not FDA approved; advisory review is not drug approval
Open recordEmideltide / DSIP
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordSemax
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordEpitalon
FDA PCAC reviewed a 503A bulk substance nomination in July 2026
Not FDA approved; advisory review is not drug approval
Open recordLL-37
Listed for forthcoming FDA PCAC consideration
Not FDA approved for marketed wellness uses; committee consideration is not approval
Open recordGHK-Cu
Listed for forthcoming FDA PCAC consideration
Not FDA approved as an injectable wellness medicine; committee consideration is not approval
Open recordDihexa acetate
Listed for forthcoming FDA PCAC consideration
Not FDA approved; committee consideration is not approval
Open recordMelanotan II
Listed for forthcoming FDA PCAC consideration
Not FDA approved; committee consideration is not approval
Open recordPEG-MGF
Listed for forthcoming FDA PCAC consideration
Not FDA approved; committee consideration is not approval
Open recordPeptide Readiness does not link to unlicensed sellers, provide dosing or reconstitution instructions, or present observed practice as a treatment recommendation.